Clinical Trial Update: Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and immunogenicity of a bivalent Norovirus VLP vaccine (GI.1/GII.4) in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• Norovirus GI.1/GII.4 bivalent virus-like particle vaccine (Norovirus GI.1/GII.4 virus-like particle vaccine)

Snippet

Sponsor: Takeda | Conditions: Healthy Volunteers | Phase 2 | Status: COMPLETED | Results posted: 2021-06-10